We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems' RTSM Momentum Signals Another Long-Term Growth Driver
Read MoreHide Full Article
Key Takeaways
VEEV secured a top-20 pharma RTSM standardization win, boosting its clinical ecosystem strategy.
Veeva sees RTSM, EDC and eCOA as a multibillion-dollar study-by-study software opportunity.
VEEV is expanding CRO partnerships to drive broader Development Cloud adoption across trials.
Veeva Systems (VEEV - Free Report) is expanding momentum in the randomization and trial supply management (“RTSM”) market, which is emerging as another important long-term growth driver for its R&D business. During the fourth quarter of fiscal 2026 earnings call, management highlighted a major top-20 pharma standardization win for its RTSM platform, underscoring growing customer confidence in Veeva Systems’ broader clinical ecosystem strategy.
Management described RTSM as a product area “as significant as the EDC area,” reflecting its mission-critical role in managing global drug supply logistics, patient randomization and trial execution. Importantly, Veeva Systems noted that large pharmaceutical customers increasingly want enterprise-scale RTSM solutions rather than relying on smaller standalone vendors, creating a favorable competitive backdrop for the company.
Veeva Systems also emphasized that the RTSM opportunity extends beyond a single product cycle and could support a broader study-by-study clinical software expansion strategy over time. Management stated that products such as RTSM, EDC and eCOA are all sold on a study-by-study basis, collectively representing a potentially multibillion-dollar opportunity. The company is additionally increasing its focus on CRO partnerships, allowing contract research organizations to offer its technologies directly within clinical trials.
This strategy could significantly expand Veeva Systems' reach across emerging biotech and midsized pharma customers while strengthening adoption of its broader Development Cloud platform. With strong execution across clinical applications and increasing enterprise standardization wins, RTSM appears well-positioned to become another meaningful growth pillar for the company in the coming years.
Peers Updates
Salesforce (CRM - Free Report) continues to expand its healthcare and enterprise AI capabilities through its Agentforce platform. The company recently partnered with HealthEx, Verily and Viz.ai to introduce AI-powered healthcare agents designed to streamline administrative and clinical workflows.
Salesforce has also strengthened its collaborations with OpenAI and Anthropic to enhance Agentforce 360, enabling enterprises to integrate advanced generative AI capabilities directly into Salesforce environments. In addition, the company expanded Agentforce 360 tools for developers and partners, reinforcing its strategy to position Salesforce as a leading enterprise AI platform across healthcare and other highly regulated industries.
IQVIA (IQV - Free Report) has also been actively strengthening its AI and drug discovery capabilities through strategic collaborations and acquisitions. Recently, the company launched IQVIA.ai, a unified agentic AI platform developed alongside NVIDIA to improve workflow automation and decision-making across clinical and commercial operations.
IQVIA also signed an agreement to acquire drug discovery assets from Charles River Laboratories, expanding its end-to-end drug discovery offerings and strengthening its presence in early-stage pharmaceutical research. Also, the company announced a strategic collaboration with Duke Clinical Research Institute focused on obesity and related disease research, further enhancing its clinical development ecosystem.
VEEV’s Price Performance, Valuation and Estimates
Shares of VEEV have plunged 28.6% in the year-to-date period compared with the industry’s decline of 22.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, VEEV trades at a price-to-book ratio of 3.61, below the industry average. RGTI carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Veeva Systems' fiscal 2027 earnings implies an 8.8% improvement from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Systems' RTSM Momentum Signals Another Long-Term Growth Driver
Key Takeaways
Veeva Systems (VEEV - Free Report) is expanding momentum in the randomization and trial supply management (“RTSM”) market, which is emerging as another important long-term growth driver for its R&D business. During the fourth quarter of fiscal 2026 earnings call, management highlighted a major top-20 pharma standardization win for its RTSM platform, underscoring growing customer confidence in Veeva Systems’ broader clinical ecosystem strategy.
Management described RTSM as a product area “as significant as the EDC area,” reflecting its mission-critical role in managing global drug supply logistics, patient randomization and trial execution. Importantly, Veeva Systems noted that large pharmaceutical customers increasingly want enterprise-scale RTSM solutions rather than relying on smaller standalone vendors, creating a favorable competitive backdrop for the company.
Veeva Systems also emphasized that the RTSM opportunity extends beyond a single product cycle and could support a broader study-by-study clinical software expansion strategy over time. Management stated that products such as RTSM, EDC and eCOA are all sold on a study-by-study basis, collectively representing a potentially multibillion-dollar opportunity. The company is additionally increasing its focus on CRO partnerships, allowing contract research organizations to offer its technologies directly within clinical trials.
This strategy could significantly expand Veeva Systems' reach across emerging biotech and midsized pharma customers while strengthening adoption of its broader Development Cloud platform. With strong execution across clinical applications and increasing enterprise standardization wins, RTSM appears well-positioned to become another meaningful growth pillar for the company in the coming years.
Peers Updates
Salesforce (CRM - Free Report) continues to expand its healthcare and enterprise AI capabilities through its Agentforce platform. The company recently partnered with HealthEx, Verily and Viz.ai to introduce AI-powered healthcare agents designed to streamline administrative and clinical workflows.
Salesforce has also strengthened its collaborations with OpenAI and Anthropic to enhance Agentforce 360, enabling enterprises to integrate advanced generative AI capabilities directly into Salesforce environments. In addition, the company expanded Agentforce 360 tools for developers and partners, reinforcing its strategy to position Salesforce as a leading enterprise AI platform across healthcare and other highly regulated industries.
IQVIA (IQV - Free Report) has also been actively strengthening its AI and drug discovery capabilities through strategic collaborations and acquisitions. Recently, the company launched IQVIA.ai, a unified agentic AI platform developed alongside NVIDIA to improve workflow automation and decision-making across clinical and commercial operations.
IQVIA also signed an agreement to acquire drug discovery assets from Charles River Laboratories, expanding its end-to-end drug discovery offerings and strengthening its presence in early-stage pharmaceutical research. Also, the company announced a strategic collaboration with Duke Clinical Research Institute focused on obesity and related disease research, further enhancing its clinical development ecosystem.
VEEV’s Price Performance, Valuation and Estimates
Shares of VEEV have plunged 28.6% in the year-to-date period compared with the industry’s decline of 22.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, VEEV trades at a price-to-book ratio of 3.61, below the industry average. RGTI carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Veeva Systems' fiscal 2027 earnings implies an 8.8% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.